What is the diagnosis and recommended management for a patient with a moderately dilated left ventricle (indexed volume ≈95 mL/m²), severe concentric left‑ventricular hypertrophy, and severely reduced systolic function?

Diagnosis and Management of Dilated Left Ventricle with Severe Concentric Hypertrophy and Reduced Systolic Function

Primary Diagnosis

This clinical presentation most likely represents end-stage hypertrophic cardiomyopathy (HCM) with systolic dysfunction and left ventricular remodeling. The combination of severe concentric left ventricular hypertrophy with moderately dilated LV cavity (indexed volume 95 mL/m²) and severely reduced systolic function indicates advanced disease with transition from the typical hypertrophic phenotype to a dilated, failing ventricle 1.

Diagnostic Considerations

• End-stage HCM occurs in approximately 3.5% of HCM patients and develops at a wide age range (14-74 years), with 45% of patients ≤40 years old 1
• The pattern of severe concentric hypertrophy with cavity dilatation represents substantial LV remodeling, which occurs in 52% of end-stage HCM patients 1
• Moderate concentric LVH with mildly-to-moderately reduced ejection fraction supports a primary cardiomyopathic process rather than secondary hypertensive changes 2
• Alternative etiologies must be systematically excluded: infiltrative diseases (amyloidosis, sarcoidosis, Fabry disease), drug-induced causes (anabolic steroids, tacrolimus, hydroxychloroquine), and severe longstanding hypertension 3, 4

Key Diagnostic Steps

• Obtain detailed family history of sudden cardiac death or cardiomyopathy to distinguish HCM from other causes 4
• Review ECG for HCM-specific patterns: deep septal Q waves or giant negative T waves 4
• Assess for left ventricular outflow tract (LVOT) obstruction with both resting gradients and provocative maneuvers, as this fundamentally alters management 2
• Cardiac MRI with late gadolinium enhancement to assess for extensive (transmural) myocardial fibrosis, which is present in most end-stage HCM patients 1
• Exclude infiltrative diseases through appropriate laboratory testing and potentially endomyocardial biopsy if clinical suspicion exists 3

Immediate Management Priorities

Guideline-Directed Medical Therapy for Heart Failure

Immediately initiate guideline-directed medical therapy for heart failure with reduced ejection fraction (HFrEF), as this is the cornerstone of treatment once systolic dysfunction develops 3, 4. This includes:

• ACE inhibitors or ARBs (losartan 50-100 mg daily preferred for superior LVH regression) 4, 2
• Beta-blockers titrated to maximum tolerated dose 3, 4
• Mineralocorticoid receptor antagonists (spironolactone or eplerenone) 3
• SGLT2 inhibitors for additional mortality benefit 3
• Diuretics for volume management, but use cautiously to avoid excessive preload reduction that can worsen hemodynamics 3, 2

Critical Medication Contraindications

If any degree of LVOT obstruction is present, immediately discontinue or avoid:

• All vasodilators including dihydropyridine calcium channel blockers, nitrates, ACE inhibitors, ARBs, and phosphodiesterase-5 inhibitors 3
• Positive inotropic agents (dobutamine, dopamine, milrinone, digoxin) 3
• High-dose diuretics that can precipitate symptomatic hypotension 3

If LVOT obstruction is present, use non-vasodilating beta-blockers (metoprolol, atenolol, propranolol) as first-line therapy instead 3, 4.

Rhythm Management

• Promptly restore sinus rhythm or achieve adequate rate control if atrial fibrillation is present or develops, as atrial contribution to ventricular filling is critical with severe LVH and reduced compliance 3, 4
• Atrial fibrillation is frequently associated with end-stage HCM and significantly worsens hemodynamics 1

Risk Stratification and Device Therapy

Sudden Cardiac Death Risk

This patient is at markedly elevated risk for sudden cardiac death. End-stage HCM with systolic dysfunction is an unfavorable complication with mortality rate of 11% per year and represents a sudden death risk factor requiring vigilance 1.

• Concentric hypertrophy is independently associated with 3.20-fold increased risk of sudden cardiac arrest (95% CI 1.90-5.39, P<0.001) even with preserved or moderately reduced LVEF 5
• Implantable cardioverter-defibrillator (ICD) placement is essential, as appropriate ICD interventions occur at 10% per year in end-stage HCM patients 1
• ICD should be placed promptly given the brief interval from end-stage onset to death/transplantation (mean 2.7±2 years) 1

Advanced Heart Failure Evaluation

Heart Transplant Assessment

Cardiopulmonary exercise testing should be performed immediately to assess candidacy for heart transplantation or mechanical circulatory support 3. This is critical because:

• 66% of end-stage HCM patients die of progressive heart failure, experience sudden death events, or require heart transplantation 1
• Duration from HCM symptom onset to end-stage identification averages 14±10 years, but progression from end-stage onset to death/transplantation is rapid (2.7±2 years) 1
• Early referral to advanced heart failure centers is mandatory given the poor prognosis and need for timely intervention 1

Monitoring and Follow-up

• Serial echocardiography every 3-6 months to monitor for further deterioration 6
• Assess for development of secondary mitral regurgitation, which commonly complicates end-stage disease 6
• Monitor for right ventricular dysfunction and pulmonary hypertension 6
• Intensive management of cardiometabolic risk factors (obesity, hypertension, diabetes, obstructive sleep apnea) is essential, as these are highly prevalent and associated with poorer prognosis 3, 4

Prognosis and Clinical Course

• Only 34% of end-stage HCM patients survive with medical management over 3±3 years 1
• Patients with systolic dysfunction (LVEF <50%) who develop from hypertensive LVH and HFpEF have significantly lower survival rates 7
• Beta-blocker therapy may play a protective role in preventing further LVEF deterioration 7
• Approximately 26.8% of patients with LV hypertrophy and HFpEF progress to systolic dysfunction over 5 years, accompanied by poor clinical outcomes 7

Common Pitfalls to Avoid

• Do not treat hypotension reflexively with inotropes if LVOT obstruction is present—this is a dangerous error that can precipitate cardiovascular collapse 3
• Do not use dobutamine stress testing to identify latent LVOT obstruction due to lack of specificity 3, 2
• Do not delay ICD placement or advanced heart failure evaluation given the rapid progression and high mortality of end-stage disease 1
• Recognize that hypotension in dynamic LVOT obstruction is driven by increased gradient rather than pump failure; therefore, increasing preload and afterload while reducing contractility paradoxically improves cardiac output 3
• Do not assume hypertensive etiology without confirming that LVH regresses with adequate blood pressure control 4